Donor-Derived Cell-Free DNA as a Companion Biomarker for AMR Treatment With Daratumumab: Case Series

Antibody-mediated rejection (AMR) is among the most frequent causes for graft loss after kidney transplantation. While there are no approved therapies, several case reports with daratumumab and the very recent phase 2 trial of felzartamab in AMR have indicated the potential efficacy of therapeutic i...

Full description

Bibliographic Details

Published in:	Transplant International
Main Authors:	Bilgin Osmanodja, Aylin Akifova, Klemens Budde, Michael Oellerich, Julia Beck, Kirsten Bornemann-Kolatzki, Ekkehard Schütz, Joachim Velden, Claudia Lehmann, Bastian Malte Krüger, Anette Bachmann, Jan Kowald
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-08-01
Subjects:	kidney transplantation antibody-mediated rejection daratumumab donor-derived cell-free DNA biomarker
Online Access:	https://www.frontierspartnerships.org/articles/10.3389/ti.2024.13213/full